Researchers Caution Against Early Immunosuppressant Reduction After Starting Soliris

Researchers Caution Against Early Immunosuppressant Reduction After Starting Soliris

286313

Researchers Caution Against Early Immunosuppressant Reduction After Starting Soliris

Early reduction of steroid and immunosuppressant therapy during Soliris (eculizumab) treatment to alleviate myasthenia gravis (MG) symptoms may result in disease aggravation and pure red cell aplasia (PRCA), according to a Japanese case study. PRCA is a form of anemia characterized by a depletion of red blood cells and red blood cell precursors in the bone marrow. “We suggest that physicians should not reduce [prednisolone] and immunosuppressants quickly after eculizumab administration,” the researchers wrote. The…

You must be logged in to read/download the full post.